Naltrexone/bupropion

Drug Profile

Naltrexone/bupropion

Alternative Names: Bupropion/naltrexone; Contrave; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; NB32

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Orexigen Therapeutics
  • Developer Kwang Dong Pharmaceutical; Orexigen Therapeutics; Valeant Pharmaceuticals International
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • No development reported Depressive disorders; Smoking withdrawal

Most Recent Events

  • 02 May 2017 Navamedic agrees to commercialise naltrexone/bupropion in Denmark, Finland, Iceland, Norway and Sweden for Obesity
  • 25 Apr 2017 Preregistration for Obesity in Canada (PO)
  • 25 Apr 2017 Health Canada accepts NDA for naltrexone/bupropion for Obesity for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top